|
|
Article: Productivity Studies Show Migraine Sufferers Get Back To Work More Quickly With Imitrex Injection
- Article from:
- PR Newswire
- Article date:
- June 30, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Key Benefit of Medication is Rapid, Effective Relief without Drowsiness
RESEARCH TRIANGLE PARK, N.C., June 30 /PRNewswire/ -- Imitrex(R) Injection (sumatriptan succinate) cut time lost at work to migraine by nearly half and alleviated headache in more than three-quarters of patients, according to studies being presented this week at the annual meeting of the American Association for the Study of Headache (AASH).
Imitrex Injection, marketed by Glaxo Wellcome Inc., is a powerful, selective serotonin (5-HT1) receptor agonist, indicated for the acute treatment of migraine with or without aura. When introduced in 1993, Imitrex Injection was the first ...